Radiation-induced oesophageal carcinoma after breast carcinoma: A report of five cases including three successfully treated by radiochemotherapy

Vuong, Nghi Tran; Boucher, Éveline; Gédouin, D; Vauléon, Élodie; Prisé, É. Le; Raoul, Jean‐Luc

doi:10.1080/02841860701338846

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most population-based studies have shown an overall higher risk of second neoplasms in breast cancer survivors than in the general population [ 3 4 5 6 7 ]. Furthermore, an increased incidence of cancer has been observed in different sites, including the contralateral breast, ovary, endometrium, thyroid gland, lung, soft tissue sarcomas, melanoma, leukemia, stomach, and colon [ 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ]. The increased risk of developing a second cancer may be related to tumor characteristics [ 16 ], therapy approach [ 8 9 10 11 12 13 14 15 16 17 18 ], or genetic factors [ 19 20 ].…”

Section: Introductionmentioning

confidence: 99%

Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study

Marcheselli

Cortesi

et al. 2015

J Breast Cancer

View full text Add to dashboard Cite

PurposeEvolving therapies have improved the prognoses of patients with breast cancer; and currently, the number of long-term survivors is continuously increasing. However, these patients are at increased risk of developing a second cancer. Thus, late side effects are becoming an important issue. In this study, we aimed to investigate whether patient and tumor characteristics, and treatment type correlate with secondary tumor risk.MethodsThis case-control study included 305 patients with a diagnosed second malignancy after almost 6 months after the diagnosis of primary breast cancer and 1,525 controls (ratio 1:5 of cases to controls) from a population-based cohort of 6,325 women. The control patients were randomly selected from the cohort and matched to the cases according to age at diagnosis, calendar period of diagnosis, disease stage, and time of follow-up.ResultsBRCA1 or BRCA2 mutation, human epidermal growth factor receptor 2 (HER2)+ status, chemotherapy, and radiotherapy were related to increased risk of developing a second cancer, whereas hormonotherapy showed a protective effect. Chemotherapy, radiotherapy, and estrogenic receptor level <10% increased the risk of controlateral breast cancer. HER2+ status increased the risk of digestive system and thyroid tumors, while BRCA1 or BRCA2 mutation increased the risk of cancer in the genital system.ConclusionBreast cancer survivors are exposed to an excess of risk of developing a second primary cancer. The development of excess of malignancies may be related either to patient and tumor characteristics, such as BRCA1 or BRCA2 mutation and HER2+ status, or to treatments factors.

show abstract